Prevalence of among asymptomatic HIV-positive and negative individuals in Central Ethiopia and efficacy of eradication therapy.

Objectives: is a widespread pathogen and major contributor to dyspeptic disease and gastric cancer. Although the interaction between HIV and infection is not well investigated, previous studies have suggested a decreased prevalence of and limited efficacy of eradication therapy in HIV-positive individuals. Therefore, the objectives of this study were to describe the prevalence of infection according to HIV status and analyze the efficacy of eradication therapy in Ethiopia.

Methods: A prospective, randomized, interventional study was performed involving HIV-positive and negative participants presenting to the Asella Referral and Teaching Hospital in Central Ethiopia between March and June 2017. A stool antigen test was used as a screening tool for infection Randomly selected patients received triple eradication therapy.

Results: The cumulative prevalence was 77.3% (392/507): 78.8% (241/306) among HIV-positive individuals versus 75.1% (151/201) among HIV-negative individuals ( = 0.386). Twenty-five HIV-positive and 26 HIV-negative -infected participants were randomized to receive standard triple therapy; three of them were lost to follow-up (one HIV-positive, two HIV-negative). The total eradication rate was 50.0%: 62.5% (15/24) among those HIV-negative versus 37.5% (9/24) among those HIV-positive [Au?1].

Conclusions: A high prevalence of was observed among HIV-positive and negative individuals in Central Ethiopia. The efficacy of eradication therapy was low, with a trend towards lower efficacy in HIV-infected individuals.